Access the full text.
Sign up today, get DeepDyve free for 14 days.
Loading next page...
/lp/oxford-university-press/current-status-of-drug-development-for-patients-with-multiple-myeloma-fwQlVs2Mu3
References (43)
-
B. Dhakal, S. Girnius, P. Hari (2016)
Recent advances in understanding multiple myelomaF1000Research, 5
-
J. Rubia, M. Sanz (2011)
Treatment of multiple myeloma in the elderly: realities and hopesLeukemia & Lymphoma, 52
-
O. Cope, S. Wyman (1948)
Multiple myeloma.The New England journal of medicine, 239 10
-
M. Tomasson, Mahmoud Ali, Vanessa Oliveira, Q. Xiao, Y. Jethava, F. Zhan, Adam Fitzsimmons, M. Bates (2018)
Prevention Is the Best Treatment: The Case for Understanding the Transition from Monoclonal Gammopathy of Undetermined Significance to MyelomaInternational Journal of Molecular Sciences, 19
-
I. Vaxman, M. Gertz (2022)
How I approach smoldering multiple myelomaBlood, 140
-
de Goeij, Bart Gijsbertus (2016)
Antibody-drug conjugates in cancer -
K. Wudhikarn, B. Wills, A. Lesokhin (2020)
Monoclonal antibodies in multiple myeloma: Current and emerging targets and mechanisms of action.Best practice & research. Clinical haematology, 33 1
-
C. Xia, Xuesi Dong, He Li, M. Cao, Dianqin Sun, Siyi He, F. Yang, Xiaoling Yan, Shaoli Zhang, Ningkang Li, Wanqing Chen (2022)
Cancer statistics in China and United States, 2022: profiles, trends, and determinantsChinese Medical Journal, 135
-
J. San-Miguel, V. Hungria, Sung-Soo Yoon, M. Beksaç, M. Dimopoulos, A. Elghandour, W. Jędrzejczak, A. Günther, T. Nakorn, N. Siritanaratkul, P. Corradini, S. Chuncharunee, Je-Jung Lee, R. Schlossman, T. Shelekhova, K. Yong, D. Tan, T. Numbenjapon, J. Cavenagh, J. Hou, R. LeBlanc, H. Nahi, L. Qiu, H. Salwender, S. Pulini, P. Moreau, K. Warzocha, D. White, J. Bladé, Wenming Chen, J. Rubia, P. Gimsing, S. Lonial, J. Kaufman, E. Ocio, Ljupco Veskovski, S. Sohn, Ming-Chung Wang, Jae Lee, H. Einsele, M. Sopala, C. Corrado, B. Bengoudifa, F. Binlich, P. Richardson (2014)
Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial.The Lancet. Oncology, 15 11
-
O. Landgren, S. Rajkumar (2011)
Development of early treatment strategies for high-risk myeloma precursor disease in the future.Seminars in hematology, 48 1
-
S. Ito (2020)
Proteasome Inhibitors for the Treatment of Multiple MyelomaCancers, 12
-
C. Varga, Michelle Maglio, I. Ghobrial, P. Richardson (2018)
Current use of monoclonal antibodies in the treatment of multiple myelomaBritish Journal of Haematology, 181
-
D. Dingli, S. Rajkumar (2010)
How best to use new therapies in multiple myeloma.Blood reviews, 24 3
-
T. Herndon, A. Deisseroth, E. Kaminskas, R. Kane, Kallappa Koti, Mark Rothmann, B. Habtemariam, J. Bullock, J. Bray, Jessica Hawes, Todd Palmby, Josephine Jee, William Adams, H. Mahayni, J. Brown, Á. Dorantes, R. Sridhara, A. Farrell, R. Pazdur (2013)
U.S. Food and Drug Administration Approval: Carfilzomib for the Treatment of Multiple MyelomaClinical Cancer Research, 19
-
C. Chim, Shaji Kumar, R. Orlowski, G. Cook, P. Richardson, M. Gertz, S. Giralt, M. Mateos, X. Leleu, K. Anderson (2017)
Management of relapsed and refractory multiple myeloma: novel agents, antibodies, immunotherapies and beyondLeukemia, 32
-
Daniel Sherbenou, T. Mark, Peter Forsberg (2017)
Monoclonal Antibodies in Multiple Myeloma: A New Wave of the FutureClinical Lymphoma, Myeloma & Leukemia, 17
-
S. Lonial, J. Kaufman, J. Laubach, P. Richardson (2013)
Elotuzumab: a novel anti-CS1 monoclonal antibody for the treatment of multiple myelomaExpert Opinion on Biological Therapy, 13
-
O. Landgren, A. Waxman (2010)
Multiple myeloma precursor disease.JAMA, 304 21
-
R. Kyle, B. Durie, S. Rajkumar, O. Landgren, J. Bladé, G. Merlini, N. Kröger, H. Einsele, D. Vesole, M. Dimopoulos, J. Miguel, H. Avet-Loiseau, R. Hájek, Wenming Chen, K. Anderson, H. Ludwig, P. Sonneveld, S. Pavlovsky, A. Palumbo, P. Richardson, B. Barlogie, P. Greipp, R. Vescio, I. Turesson, J. Westin, M. Boccadoro (2010)
Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and managementLeukemia, 24
-
Fengjuan Fan, A. Schimming, D. Jaeger, K. Podar (2011)
Targeting the Tumor Microenvironment: Focus on AngiogenesisJournal of Oncology, 2012
-
Connie Kang (2022)
Teclistamab: First ApprovalDrugs, 82
-
M. Farrell, M. Reagan (2018)
Soluble and Cell–Cell-Mediated Drivers of Proteasome Inhibitor Resistance in Multiple MyelomaFrontiers in Endocrinology, 9
-
D. Pulte, L. Jansen, F. Castro, K. Emrich, A. Katalinic, B. Holleczek, H. Brenner (2015)
Trends in survival of multiple myeloma patients in Germany and the United States in the first decade of the 21st centuryBritish Journal of Haematology, 171
-
C Fitzmaurice, D Abate (2019)
Global, regional, and National Cancer Incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 29 cancer groups, 1990 to 2017: a systematic analysis for the global burden of disease study, 5
-
CH Chau, PS Steeg, WD Figg (2019)
Antibody-drug conjugates for cancer, 394
-
P. Fayers, A. Palumbo, C. Hulin, A. Waage, P. Wijermans, M. Beksaç, S. Bringhen, J. Mary, P. Gimsing, F. Termorshuizen, R. Haznedar, T. Caravita, P. Moreau, I. Turesson, P. Musto, L. Benboubker, M. Schaafsma, P. Sonneveld, T. Facon (2011)
Thalidomide for previously untreated elderly patients with multiple myeloma: meta-analysis of 1685 individual patient data from 6 randomized clinical trials.Blood, 118 5
-
Sarakshi Mahajan, N. Tandon, Shaji Kumar (2018)
The evolution of stem-cell transplantation in multiple myelomaTherapeutic Advances in Hematology, 9
-
M. Offidani, L. Corvatta, S. Gentili (2018)
Triplet vs. doublet drug regimens for managing multiple myelomaExpert Opinion on Pharmacotherapy, 19
-
Sheridan Hoy (2017)
Pomalidomide: A Review in Relapsed and Refractory Multiple MyelomaDrugs, 77
-
M. Dimopoulos, S. Lonial, D. White, P. Moreau, K. Weisel, J. San-Miguel, O. Shpilberg, S. Grosicki, I. Špička, A. Walter‐Croneck, H. Magen, M. Mateos, A. Belch, D. Reece, M. Beksaç, A. Spencer, H. Oakervee, R. Orlowski, M. Taniwaki, C. Röllig, H. Einsele, M. Matsumoto, K. Wu, K. Anderson, Ying‐Ming Jou, A. Ganetsky, A. Singhal, P. Richardson (2020)
Elotuzumab, lenalidomide, and dexamethasone in RRMM: final overall survival results from the phase 3 randomized ELOQUENT-2 studyBlood Cancer Journal, 10
-
A. Chanan-Khan, I. Borrello, Kelvin Lee, D. Reece (2010)
Development of target‐specific treatments in multiple myelomaBritish Journal of Haematology, 151
-
B. Durie (2010)
Role of new treatment approaches in defining treatment goals in multiple myeloma--the ultimate goal is extended survival.Cancer treatment reviews, 36 Suppl 2
-
Shaji Kumar (2010)
Multiple myeloma - current issues and controversies.Cancer treatment reviews, 36 Suppl 2
-
Omar Alkharabsheh, Z. Trisel, Sunil Badami, M. Aljama, M. Sidiqi (2021)
Checkpoint Inhibitors in Multiple Myeloma: Intriguing Potential and Unfulfilled PromisesCancers, 14
-
X. Chang, Y. Zhu, C. Shi, A. Stewart (2014)
Mechanism of immunomodulatory drugs' action in the treatment of multiple myeloma.Acta biochimica et biophysica Sinica, 46 3
-
P. Moreau, A. Garfall, N. Donk, H. Nahi, J. San-Miguel, A. Oriol, A. Nooka, T. Martin, L. Rosiñol, A. Chari, L. Karlin, L. Benboubker, M. Mateos, N. Bahlis, R. Popat, B. Besemer, J. Martínez-López, S. Sidana, M. Delforge, L. Pei, D. Trancucci, R. Verona, S. Girgis, S. Lin, Y. Olyslager, M. Jaffe, C. Uhlar, T. Stephenson, R. Rampelbergh, A. Banerjee, J. Goldberg, R. Kobos, A. Krishnan, S. Usmani (2022)
Teclistamab in Relapsed or Refractory Multiple Myeloma.The New England journal of medicine
-
M. Dimopoulos, P. Richardson, N. Bahlis, S. Grosicki, M. Cavo, M. Beksaç, W. Legiec, A. Liberati, H. Goldschmidt, A. Belch, H. Magen, A. Larocca, J. Laubach, M. Petrucci, D. Reece, D. White, M. Mateos, I. Špička, M. Lazaroiu, J. Berdeja, J. Kaufman, Ying‐Ming Jou, A. Ganetsky, Mihaela Mckiver, S. Lonial, K. Weisel (2022)
Addition of elotuzumab to lenalidomide and dexamethasone for patients with newly diagnosed, transplantation ineligible multiple myeloma (ELOQUENT-1): an open-label, multicentre, randomised, phase 3 trial.The Lancet. Haematology
-
M. Mateos, O. Landgren (2016)
MGUS and Smoldering Multiple Myeloma: Diagnosis and Epidemiology.Cancer treatment and research, 169
-
Sydney Lu (2020)
Modern treatments and future directions for newly diagnosed multiple myeloma patients.Best practice & research. Clinical haematology, 33 1
-
M. Dimopoulos, I. Ntanasis-Stathopoulos, E. Terpos (2019)
Real World Treatment of Patients with Relapsed/Refractory MyelomaClinical Lymphoma Myeloma and Leukemia
-
E. Maiese, K. Evans, B. Chu, D. Irwin (2018)
Temporal Trends in Survival and Healthcare Costs in Patients with Multiple Myeloma in the United States.American health & drug benefits, 11 1
-
D. Vogl, D. Dingli, R. Cornell, C. Huff, S. Jagannath, D. Bhutani, J. Zonder, R. Baz, Ajay Nooka, A. Nooka, J. Richter, C. Cole, R. Vij, A. Jakubowiak, R. Abonour, G. Schiller, Terri Parker, L. Costa, D. Kaminetzky, J. Hoffman, A. Yee, A. Chari, D. Siegel, R. Fonseca, S. Wier, G. Ahmann, Ilse Lopez, M. Kauffman, S. Shacham, J. Saint-Martin, Carla Picklesimer, C. Choe-Juliak, A. Stewart (2018)
Selective Inhibition of Nuclear Export With Oral Selinexor for Treatment of Relapsed or Refractory Multiple Myeloma.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 36 9
-
A. Stewart (2009)
Novel therapies for relapsed myeloma.Hematology. American Society of Hematology. Education Program
- Publisher
- Oxford University Press
- Copyright
- © The Author(s) 2023. Published by Oxford University Press on behalf of Antibody Therapeutics. All rights reserved. For Permissions, please email: journals.permissions@oup.com
- eISSN
- 2516-4236
- DOI
- 10.1093/abt/tbad010
- Publisher site
- See Article on Publisher Site
Abstract
Multiple myeloma (MM) is a highly heterogeneous malignancy. The treatment of MM has been significantly advanced in recent years. B cell maturation antigen (BCMA)-targeted immunotherapy and chimeric antigen receptor T (CAR-T) cell therapy have been approved for the treatment of relapsed and refractory MM (RRMM), which will be launched in China shortly. The CD38 (cluster of differentiation 38) antibody, daratumumab, improves the clinical outcomes both RRMM and newly diagnosed MM patients. The combination of daratumumab, bortezomib and dexamethasone achieved favorable outcomes as the first-line therapy in China. However, high-risk patients have limited benefits from these advanced therapeutics, and usually relapse early, progressing into aggressive end-stage MM. Therefore, novel therapies are sought to improve the cancer prognosis in these patients. This review furnishes an overview of the recent clinical developments of these novel drugs and compares the drug candidates under development in China to the rest of the world.
Journal
Antibody Therapeutics – Oxford University Press
Published: May 11, 2023
Keywords: multiple myeloma; drug development; therapeutic modality; immunotherapy; clinical progress